Current and historical daily PE Ratio for SK Bioscience Co Ltd (
) from 2021 to Apr 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. SK Bioscience stock (XKRX:302440) PE ratio as of Apr 23 2024 is 203.13.
More Details
SK Bioscience Co Ltd (XKRX:302440) PE Ratio (TTM) Chart
SK Bioscience Co Ltd (XKRX:302440) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 796
- 1
- 2
- 3
- 4
- 5
- 6
- 9
| SK Bioscience PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-23 | 203.1 | 2024-02-16 | 225.0 |
| 2024-04-22 | 203.1 | 2024-02-15 | 223.6 |
| 2024-04-19 | 199.3 | 2024-02-14 | 224.7 |
| 2024-04-18 | 202.1 | 2024-02-13 | 226.4 |
| 2024-04-17 | 196.9 | 2024-02-08 | 225.3 |
| 2024-04-16 | 197.9 | 2024-02-07 | 225.0 |
| 2024-04-15 | 203.8 | 2024-02-06 | 220.8 |
| 2024-04-12 | 208.7 | 2024-02-05 | 221.9 |
| 2024-04-11 | 207.3 | 2024-02-02 | 224.7 |
| 2024-04-09 | 208.0 | 2024-02-01 | 222.6 |
| 2024-04-08 | 208.7 | 2024-01-31 | 220.5 |
| 2024-04-05 | 207.3 | 2024-01-30 | 224.3 |
| 2024-04-04 | 206.3 | 2024-01-29 | 224.3 |
| 2024-04-03 | 206.6 | 2024-01-26 | 220.5 |
| 2024-04-02 | 210.1 | 2024-01-25 | 220.8 |
| 2024-04-01 | 214.6 | 2024-01-24 | 220.1 |
| 2024-03-29 | 212.8 | 2024-01-23 | 221.5 |
| 2024-03-28 | 214.2 | 2024-01-22 | 218.1 |
| 2024-03-27 | 215.3 | 2024-01-19 | 218.8 |
| 2024-03-26 | 218.4 | 2024-01-18 | 217.0 |
| 2024-03-25 | 217.0 | 2024-01-17 | 220.1 |
| 2024-03-22 | 218.8 | 2024-01-16 | 228.5 |
| 2024-03-21 | 217.7 | 2024-01-15 | 228.5 |
| 2024-03-20 | 213.9 | 2024-01-12 | 231.9 |
| 2024-03-19 | 209.7 | 2024-01-11 | 236.8 |
| 2024-03-18 | 212.5 | 2024-01-10 | 236.5 |
| 2024-03-15 | 210.1 | 2024-01-09 | 236.8 |
| 2024-03-14 | 212.8 | 2024-01-08 | 235.8 |
| 2024-03-13 | 212.8 | 2024-01-05 | 239.2 |
| 2024-03-12 | 217.0 | 2024-01-04 | 243.1 |
| 2024-03-11 | 214.6 | 2024-01-03 | 253.1 |
| 2024-03-08 | 217.0 | 2024-01-02 | 254.5 |
| 2024-03-07 | 213.2 | 2023-12-28 | 250.0 |
| 2024-03-06 | 210.4 | 2023-12-27 | 119.7 |
| 2024-03-05 | 212.5 | 2023-12-26 | 118.3 |
| 2024-03-04 | 211.1 | 2023-12-22 | 116.8 |
| 2024-02-29 | 213.2 | 2023-12-21 | 115.8 |
| 2024-02-28 | 216.7 | 2023-12-20 | 118.2 |
| 2024-02-27 | 219.1 | 2023-12-19 | 116.2 |
| 2024-02-26 | 222.6 | 2023-12-18 | 116.0 |
| 2024-02-23 | 221.9 | 2023-12-15 | 116.3 |
| 2024-02-22 | 222.6 | 2023-12-14 | 116.5 |
| 2024-02-21 | 225.7 | 2023-12-13 | 114.3 |
| 2024-02-20 | 225.7 | 2023-12-12 | 117.7 |
| 2024-02-19 | 225.0 | 2023-12-11 | 117.3 |
SK Bioscience Co Ltd (XKRX:302440) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
SK Bioscience Co Ltd
ISIN : KR7302440003
Compare
Compare
Traded in other countries / regions
302440.Korea IPO Date
2021-03-18Description
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers